These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3654927)

  • 1. Metabolism and serum binding of RU 486 in women after various single doses.
    Heikinheimo O; Lähteenmäki PL; Koivunen E; Shoupe D; Croxatto H; Luukkainen T; Lähteenmäki P
    Hum Reprod; 1987 Jul; 2(5):379-85. PubMed ID: 3654927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of RU 486.
    Lähteenmäki P; Heikinheimo O; Croxatto H; Spitz I; Shoupe D; Birgerson L; Luukkainen T
    J Steroid Biochem; 1987; 27(4-6):859-63. PubMed ID: 3695508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
    Heikinheimo O; Kontula K; Croxatto H; Spitz I; Luukkainen T; Lähteenmäki P
    J Steroid Biochem; 1987 Feb; 26(2):279-84. PubMed ID: 3560943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of RU 486 and its demethylated metabolites in humans.
    Heikinheimo O; Haukkamaa M; Lähteenmäki P
    J Clin Endocrinol Metab; 1989 Feb; 68(2):270-5. PubMed ID: 2918046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response relationships of RU 486.
    Heikinheimo O; Kekkonen R
    Ann Med; 1993 Feb; 25(1):71-6. PubMed ID: 8382070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action.
    Heikinheimo O; Kekkonen R; Lähteenmäki P
    Contraception; 2003 Dec; 68(6):421-6. PubMed ID: 14698071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans.
    Heikinheimo O
    Acta Obstet Gynecol Scand; 1990; 69(4):357-8. PubMed ID: 2244471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of mifepristone.
    Heikinheimo O
    Clin Pharmacokinet; 1997 Jul; 33(1):7-17. PubMed ID: 9250420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose.
    Cekan S; Aedo AR; Segerstéen E; Van Look P; Messinis I; Templeton A
    Hum Reprod; 1989 Feb; 4(2):131-5. PubMed ID: 2918065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration.
    Heikinheimo O
    J Steroid Biochem; 1989 Jan; 32(1A):21-5. PubMed ID: 2913396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic metabolism and distribution of mifepristone and its metabolites in rats.
    Heikinheimo O; Pesonen U; Huupponen R; Koulu M; Lähteenmäki P
    Hum Reprod; 1994 Jun; 9 Suppl 1():40-6. PubMed ID: 7962468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography.
    Heikinheimo O; Tevilin M; Shoupe D; Croxatto H; Lähteenmäki P
    Contraception; 1986 Dec; 34(6):613-24. PubMed ID: 3829676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the progesterone antagonist 17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)-17 alpha-(1-propynyl) estra-4,9-dien-3-one in the rabbit.
    Wang G; Aedo AR; Cekan SZ
    Arzneimittelforschung; 1986 Jun; 36(6):936-8. PubMed ID: 3741527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro study of the binding of RU 486 and RU 42 633 to human serum proteins.
    Grimaldi B; Hamberger C; Tremblay D; Barre J; Tillement JP
    Prog Clin Biol Res; 1989; 300():445-8. PubMed ID: 2780642
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the antiglucocorticoid RU 486 on adrenal function in dogs.
    Wade CE; Spitz IM; Lahteenmaki P; Heikinheimo O; Krieger DT; Bardin CW
    J Clin Endocrinol Metab; 1988 Mar; 66(3):473-9. PubMed ID: 2832437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man.
    Kawai S; Nieman LK; Brandon DD; Udelsman R; Loriaux DL; Chrousos GP
    J Pharmacol Exp Ther; 1987 May; 241(2):401-6. PubMed ID: 3572801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans.
    Heikinheimo O; Croxatto H; Salvatierra AM; Chang CC; Luukkainen T; Lähteenmäki P
    Hum Reprod; 1987 Nov; 2(8):645-8. PubMed ID: 3437043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental demonstration in the rat of the role played by human alpha 1 glycoprotein (HAAG) in the nonlinearity of RU 486 pharmacokinetics in women.
    Tremblay D; Busigny M; Bonnat C; Pottier J
    Prog Clin Biol Res; 1989; 300():441-4. PubMed ID: 2528733
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors affecting serum protein binding of cocaine in humans.
    Parker RB; Williams CL; Laizure SC; Lima JJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):605-10. PubMed ID: 7473145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.